Prognostic Gene Expression-Based Signature in Clear-Cell Renal Cell Carcinoma

Roldán, Fiorella L.; Izquierdo, Laura; Ingelmo-Torres, Mercedes; Lozano, Juan José; Carrasco, Raquel Castellano; Cuñado, Alexandra; Reig, Òscar; Mengual, Lourdes; Alcaraz, Antonio

doi:10.3390/cancers14153754

Cited by 15 publications

(14 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistently, the current study also showed that GNLY is specifically expressed in bladder cancer T cells. CERCAM is an adhesion molecule whose expression is at high levels in brain microvasculature, which leukocytes can use to stretch across the blood–brain barrier, regulate leukocyte migration capacity and adhesion, and has been found to be a negative prognostic marker in several tumors 41 – 43 . Its overexpression promotes cell viability, proliferation, and invasion and is associated with the PI3K/AKT pathway 44 .…”

Section: Discussionmentioning

confidence: 99%

The prognostic value of hedgehog signaling in bladder cancer by integrated bioinformatics

Li²,

Feng³

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Bladder cancer is the second most prevalent urological malignancy. It's a big contributor to cancer-related deaths throughout the globe. Researchers discovered that the hedgehog signaling (HhS) pathway contributed to the onset and spread of many different kinds of cancer. Nevertheless, the present understanding of the function of HhS in the bladder cancer molecular landscape is incomplete. Raw data were gotten from the IMvigor210, the Gene Expression Omnibus, and The Cancer Genome Atlas databases. Bioinformatics was used to examine the HhS score of each sample, and the enrichment of differentially expressed genes (DEGs), differentiation characteristics, immunological infiltration, and metabolic activity. The HhS prognostic signature was developed with significant assistance from the least absolute shrinkage and selection operator regression and Cox regression. An HhS-related nomogram was developed to assist in the prediction of patients’ survival probability. We found that HhS was linked to poor prognosis in bladder cancer, and its activation was linked to the Basal subtype of bladder cancer. Bladder cancer with high HhS activity has higher glycolysis, nucleotide metabolism, amino acid metabolism, and other cancer-promoting metabolic activities. Furthermore, HhS mediates an immunosuppressive microenvironment in bladder cancer on the basis that HhS negatively correlates with the CD8 + T cells and correlates positively with immune checkpoints and T cell exhaustion scores. Finally, an HhS-related signature was developed for predicting the prognosis of patients with bladder cancer. Targeting HhS may be a potential therapy choice for bladder cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

The prognostic value of hedgehog signaling in bladder cancer by integrated bioinformatics

Li²,

Feng³

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…CERCAM, as a gene associated with cell adhesion as well as extracellular matrix remodeling, its role in tumors is mainly to promote tumor epithelial cell migration and promote cancer progression(46). Although it has been found that the expression level of CERCAM in Colon Cancer and kidney cancer affects the prognostic level of tumors (47,48). However, in head and neck squamous carcinoma, the prognostic signi cance and biological functions of CERCAM have never been elucidated.…”

Section: Discussionmentioning

confidence: 99%

CERCAM is a prognostic biomarker associated with immune infiltration of macrophage M2 polarization in head and neck squamous carcinoma

Yang

Yan²,

Chen

2023

Preprint

View full text Add to dashboard Cite

Purpose This study aimed to investigate the relevance of cerebral endothelial cell adhesion molecule (CERCAM) expression to head and neck squamous cell carcinoma (HNSCC) prognosis and immune infiltration by macrophage M2 polarization. Methods Timer, UALCAN and HPA databases was used to analyze the differences in mRNA and protein levels of CERCAM expression in HNSCC. The Timer database was also applied to analyze the correlation between CERCAM in HNSCC and immune infiltration. TCGA-HNSCC database was applied to analyze the correlation between CERCAM expression levels and clinicopathological features, and its diagnostic and prognostic value in HNSCC was also assessed. The cBioPortal and MethSurv databases were then applied to analyze the genetic variation and methylation status of CERCAM. In vitro cellular assays were performed to provide evidence that CERCAM promotes malignant biological behavior of tumors and promotes macrophage M2 polarization in tumors. Finally, underlying pathophysiological mechanisms of CERCAM involvement in the development of HNSCC were predicted using a bioinformatics approach. Results CERCAM is significantly overexpressed in HNSCC and correlates with poor prognostic levels and has good performance in predicting survival status in HNSCC patients. Cox regression analysis indicates that CERCAM expression levels are independent risk factors for predicting OS, DSS, and PFI. CERCAM promotes tumor malignant biological behavior and promotes macrophage M2 polarization immune infiltration in HNSCC. In addition, CERCAM promotes tumor cell adhesion in head and neck squamous carcinoma and promotes tumor progression through several oncogenic signaling pathways. Conclusion CERCAM may serve as a new diagnostic and prognostic biomarker in HNSCC and is a promising therapeutic target for HNSCC.

show abstract

“…Fourth, PD-L1 expression status was analyzed in tumor-infiltrating immune cells but not in tumor cells. Factors that were not considered in this study, such as PD-L1 expression status in tumor cells and gene expression [ 31 , 32 ] or mutation analysis, should be investigated in the future.…”

Section: Discussionmentioning

confidence: 99%

The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis

Fujita

Kimura

Tsuzuki

et al. 2022

Cancers

View full text Add to dashboard Cite

Biological or immunological differences in primary lesions between synchronous and metachronous metastatic renal cell carcinoma (mRCC) have been reported. However, the association between the tumor immune microenvironment (TIME) of primary lesions and time to metastasis remains unknown. We investigated the differences in the TIME of primary lesions based on time intervals to metastasis, mainly between the synchronous group (SG; metastasis within 3 months) and metachronous group (MG; metastasis after 3 months), and its association with clinicopathological parameters in patients with mRCC. Overall, 568 patients treated first-line with vascular endothelial growth factor receptor inhibitors comprised the analysis population (SG: N = 307 [54.0%]; MG: N = 261 [46.0%]). SG had a higher proportion of patients with poor prognostic pathological feature tumors: WHO/ISUP grade 4, necrosis, lymphovascular invasion, infiltrative growth pattern, and sarcomatoid differentiation. Regarding the TIME, more immunogenic features were seen in SG than MG, with a higher PD-L1 positivity and a lower proportion of the desert phenotype. This is the first study to examine the differences in the TIME of primary lesions in patients with mRCC based on the time intervals to metastasis. The TIME of primary lesions could affect the time to metastasis.

show abstract

Prognostic Gene Expression-Based Signature in Clear-Cell Renal Cell Carcinoma

Cited by 15 publications

References 48 publications

The prognostic value of hedgehog signaling in bladder cancer by integrated bioinformatics

The prognostic value of hedgehog signaling in bladder cancer by integrated bioinformatics

CERCAM is a prognostic biomarker associated with immune infiltration of macrophage M2 polarization in head and neck squamous carcinoma

The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis

Contact Info

Product

Resources

About